AlphaValue Corporate Services
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things are getting going...hopefully in FY25
Target
Upside 294%
Price (€) 1.71
Market Cap (€M) 76.7
Perf. 1W: -6.15%
Perf. 1M: 3.46%
Perf. 3M: -4.81%
Perf Ytd: -21.7%
10 day relative perf. to stoxx600: -3.16%
20 day relative perf. to stoxx600: 3.46%
Financing issue 06/04/2017 16:40

The capital increase was successful

Fact

The capital increase was 137% subscribed, raising the group equity by some €4.98m gross after the exercise of the 15% extension clause.


Analysis

As a reminder, the capital increase was carried out from 16 to 30 March at €4.5 per share. As a result of this successful operation, the number of shares will rise by 1.107m (to be listed as of 7 April) to 8,813m. The company will also have enough cash to finance the next two financial years, even before partnerships and tax credits (CIR).


Impact

We will fine-tune our numbers, based on the outcome of the capital increase, but this will only be marginal since we have already taken into account this new issue.


Updates
.